Edwards Lifesciences Receives FDA Approval for Tricuspid Valve Repair System
Edwards Lifesciences has secured US FDA approval for its tricuspid valve repair system, marking a significant milestone for its structural heart disease portfolio.
Stocks · News reference
Edwards Lifesciences Says FDA Approves AUTUS Size-Adjustable Valve, Surgical Pulmonary Valve Designed For Pediatric Patients With Congenital Heart Disease
Edwards Lifesciences (NYSE:EW) today announced that the U.S. Food and Drug Administration (FDA) has approved the AUTUS Size-Adjustable Valve, a surgical pulmonary valve designed specifically for pediatric patients with
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
FDA Flags High-Risk Heart Device Recall At Edwards Lifesciences After Patient Death
Edwards Lifesciences recalls Commander M delivery systems following balloon burst reports and 1 death. Read the FDA alert.
Reported Earlier, Edwards Lifesciences Tells Customers To Remove Four Lots Of Commander M Delivery Systems For SAPIEN M3; FDA Flags Potentially High-Risk Issue
https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-transcatheter-mitral-valve-delivery-system-issue-edwards-lifesciences
Barclays Initiates Coverage On Edwards Lifesciences with Overweight Rating, Announces Price Target of $110
Barclays analyst Christopher Pasquale initiates coverage on Edwards Lifesciences (NYSE:EW) with a Overweight rating and announces Price Target of $110.